Ceryvyn Therapeutics Limited (ASX:CYV)
Australia · Delayed Price · Currency is AUD 0.0100
0.00 (0.00%)
Sep 18, 2026, 4:10 PM AEST
Ceryvyn Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 30.02 | 73.94 | 258.5 | 134.01 | 64.78 |
Cash & Short-Term Investments | 30.02 | 73.94 | 258.5 | 134.01 | 64.78 |
Cash Growth | -59.40% | -71.39% | 92.90% | 106.87% | -58.91% |
Other Receivables | 1.1 | 11.61 | 17.72 | 9.86 | 9.52 |
Receivables | 1.1 | 11.61 | 17.72 | 9.86 | 9.52 |
Prepaid Expenses | 0.81 | 1.15 | 5.84 | 3.96 | 12.66 |
Total Current Assets | 31.93 | 86.7 | 282.06 | 147.83 | 86.95 |
Property, Plant & Equipment | - | - | 0.2 | 0.3 | 0.04 |
Other Long-Term Assets | - | - | 0.7 | 0.08 | 0.16 |
Total Assets | 31.93 | 86.7 | 282.96 | 148.21 | 87.15 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accrued Expenses | - | 1.74 | 1.59 | 1.21 | 0.93 |
Current Portion of Long-Term Debt | - | 377.01 | - | - | - |
Current Portion of Leases | - | - | 0.14 | 0.15 | - |
Other Current Liabilities | 2.32 | 14.86 | 94.27 | 26.81 | 16.55 |
Total Current Liabilities | 2.32 | 393.61 | 96.01 | 28.16 | 17.48 |
Long-Term Debt | - | - | 300.56 | 128.7 | - |
Long-Term Leases | - | - | - | 0.13 | - |
Other Long-Term Liabilities | - | - | 0.01 | 0.01 | 0.04 |
Total Liabilities | 2.32 | 393.61 | 396.58 | 157 | 17.52 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 732.47 | 728 | 698.57 | 482.13 | 341.48 |
Retained Earnings | -759.61 | -1,090 | -868.86 | -540.09 | -314.87 |
Comprehensive Income & Other | 56.76 | 55.15 | 56.67 | 49.17 | 43.02 |
Shareholders' Equity | 29.62 | -306.91 | -113.62 | -8.79 | 69.63 |
Total Liabilities & Equity | 31.93 | 86.7 | 282.96 | 148.21 | 87.15 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | - | 377.01 | 300.7 | 128.98 | - |
Net Cash (Debt) | 30.02 | -303.07 | -42.2 | 5.03 | 64.78 |
Net Cash Growth | - | - | - | -92.24% | -58.87% |
Net Cash Per Share | 0.02 | -0.25 | -0.07 | 0.01 | 0.18 |
Filing Date Shares Outstanding | 1,368 | 1,231 | 1,231 | 467.16 | 352.15 |
Total Common Shares Outstanding | 1,368 | 1,231 | 1,091 | 467.16 | 352.15 |
Working Capital | 29.62 | -306.91 | 186.06 | 119.66 | 69.47 |
Book Value Per Share | 0.02 | -0.25 | -0.10 | -0.02 | 0.20 |
Tangible Book Value | 29.62 | -306.91 | -113.62 | -8.79 | 69.63 |
Tangible Book Value Per Share | 0.02 | -0.25 | -0.10 | -0.02 | 0.20 |